Cholesterol Ratio Calculator
Reviewed by Hamza Gujjar, Algorithm Architect & Software Developer
Last updated: August 20, 2026A Ratio That Reads Differently Than Either Number Alone
Total cholesterol and HDL ("good") cholesterol each tell part of the story, but the ratio between them is what many cardiovascular risk assessments actually use, since a high total cholesterol paired with high HDL reads very differently than the same total paired with low HDL. This calculator produces that ratio directly, and can estimate LDL from triglycerides when it isn't measured separately.
The Formula
Risk Categories
| TC/HDL ratio | Category |
|---|---|
| Below 3.5 | Optimal / Low Risk |
| 3.5 – 5.0 | Average Risk |
| Above 5.0 | High Risk |
Estimating LDL When It Isn't Given
LDL = Total Cholesterol − HDL − (Triglycerides ÷ 5) (mg/dL, divisor 2.2 for mmol/L)
This estimate is only valid when triglycerides are below 400 mg/dL (4.5 mmol/L) — above that threshold, the Friedewald formula becomes unreliable and the calculator flags the LDL estimate as unavailable rather than returning an inaccurate figure.
Why the Ratio Gets Used Alongside Raw Numbers
- Routine cardiovascular screening — the TC/HDL ratio is one of several figures reviewed alongside individual cholesterol values during a standard lipid panel review.
- Comparing HDL's protective effect — because HDL helps clear cholesterol from the bloodstream, a favorable ratio can occur even with a moderately elevated total cholesterol, if HDL is also high.
- Tracking change over time — watching the ratio trend across repeat lipid panels can be more informative than any single reading.
How to Use This Calculator
- Select your unit: mg/dL or mmol/L.
- Enter your total cholesterol and HDL values.
- Optionally enter LDL directly, or enter triglycerides to estimate LDL via the Friedewald formula.
- Select Calculate to see your TC/HDL ratio, risk category, and LDL/HDL ratio if available.
Related Calculations
Check blood pressure alongside cholesterol with the Blood Pressure Calculator, or overall lifestyle risk factors with the Life Expectancy Calculator.
Principles of Cardiovascular Lipid Risk: Cholesterol Ratios
A cholesterol ratio calculator evaluates cardiovascular atherosclerotic disease risk by computing the mathematical ratios between different lipoprotein fractions. In cardiology and preventive medicine, Cholesterol Ratios provide a more comprehensive assessment of heart disease risk than isolated LDL cholesterol alone.
The Fundamental Cholesterol Ratio Formulas
LDL / HDL Ratio = LDL Cholesterol (mg/dL) / HDL Cholesterol (mg/dL)
Triglyceride / HDL Ratio = Triglycerides (mg/dL) / HDL Cholesterol (mg/dL)
Non-HDL Cholesterol = Total Cholesterol - HDL Cholesterol
Cardiovascular Risk Benchmarks by Cholesterol Ratio
| Cholesterol Ratio Metric | Optimal (Low Risk) | Elevated Risk | High Risk |
|---|---|---|---|
| Total Cholesterol / HDL Ratio | < 3.5 : 1 | 3.5 to 5.0 | > 5.0 : 1 |
| LDL / HDL Ratio | < 2.0 : 1 | 2.0 to 3.5 | > 3.5 : 1 |
| Triglyceride / HDL Ratio | < 2.0 : 1 | 2.0 to 4.0 | > 4.0 : 1 (Insulin Resistance Marker) |
The Friedewald Equation for Calculated LDL
Valid only when Triglycerides < 400 mg/dL; use direct LDL assay for higher values.
Statin Therapy ACC/AHA Guidelines
- LDL ≥ 190 mg/dL: High-intensity statin therapy (Atorvastatin 40 to 80 mg) regardless of ASCVD risk score.
- Diabetic patients aged 40 to 75: Moderate-intensity statin therapy (Rosuvastatin 10 mg).
- 10-Year ASCVD Risk ≥ 7.5%: Shared decision-making for moderate-to-high intensity statin initiation.
ApoB and Lipoprotein(a) as Advanced Lipid Markers
Beyond standard cholesterol ratios, advanced cardiovascular risk assessment measures Apolipoprotein B (ApoB) and Lipoprotein(a) [Lp(a)]:
Lp(a) (Elevated Risk Threshold): > 50 mg/dL or > 125 nmol/L
Elevated Lp(a) is a genetically inherited independent cardiovascular risk factor affecting approximately 20% of the global population, currently untreatable with statin therapy alone but targeted by emerging antisense oligonucleotide (ASO) therapeutics.
Non-HDL Cholesterol: The Comprehensive Atherogenic Marker
Non-HDL Cholesterol captures all atherogenic lipoproteins (LDL, VLDL, IDL, and Lp(a)) in a single measurement:
- Optimal Non-HDL Cholesterol: < 130 mg/dL for standard risk patients.
- High-Risk Patients (Diabetes, ASCVD): Non-HDL Cholesterol target < 100 mg/dL.
Unlike LDL, Non-HDL Cholesterol does not require fasting blood specimens, making it a practical and superior risk metric in routine clinical lipid screening.
PCSK9 Inhibitors for Severe Hypercholesterolemia
For patients with familial hypercholesterolemia (FH) or ASCVD who fail to achieve LDL goals despite maximum statin therapy:
PCSK9 Monoclonal Antibody Injections (Evolocumab / Alirocumab) reduce LDL cholesterol by an additional 50% to 60%, achieving LDL levels as low as 20 to 30 mg/dL, dramatically reducing major adverse cardiovascular event rates.
Coronary Artery Calcium (CAC) Score Integration
For patients with borderline cholesterol ratios (TC/HDL = 4.0 to 5.0) and intermediate 10-Year ASCVD risk:
- CAC Score = 0: Very low risk (< 5% 10-year ASCVD); may defer statin therapy with lifestyle optimization.
- CAC Score 1 to 99: Moderate risk; statin initiation recommended for patients ≥ 55 years.
- CAC Score ≥ 100: Elevated plaque burden; high-intensity statin therapy strongly recommended regardless of calculated cholesterol ratios.
Triglyceride-to-HDL Ratio as an Insulin Resistance Surrogate
The Triglyceride/HDL Ratio serves as a powerful surrogate biomarker for insulin resistance and metabolic syndrome:
Lifestyle Interventions for Cholesterol Ratio Improvement
- Exercise: Regular moderate-intensity aerobic exercise (150 minutes per week) raises HDL cholesterol by 5% to 10%, directly improving all cholesterol ratio metrics.
- Dietary Omega-3 Fatty Acids: EPA and DHA from fatty fish (salmon, mackerel) or prescription icosapent ethyl (Vascepa) reduce triglycerides by 20% to 45%.
- Weight Loss: Every 10 pounds of weight loss improves HDL by approximately 1 mg/dL and reduces triglycerides by 5% to 10%.
Familial Hypercholesterolemia (FH) Screening
Patients presenting with extremely elevated cholesterol ratios (TC/HDL > 8.0) and LDL cholesterol > 190 mg/dL should be evaluated for Familial Hypercholesterolemia (FH):
FH is a common autosomal dominant genetic disorder affecting approximately 1 in 250 individuals worldwide, caused by mutations in the LDL receptor gene (LDLR), apolipoprotein B gene (APOB), or PCSK9 gene. Without aggressive lipid-lowering treatment, heterozygous FH patients face a 50% risk of coronary events before age 50 in men and age 60 in women.
Annual Lipid Panel Screening Recommendations
The American Heart Association and ACC recommend fasting lipid panel screening every 4 to 6 years for average-risk adults beginning at age 20, with more frequent annual monitoring for patients on statin therapy, those with established ASCVD, diabetes mellitus, familial hypercholesterolemia, or metabolic syndrome.